Fabry disease and the skin: data from FOS, the Fabry outcome survey
Catherine H. Orteu(Royal Free London NHS Foundation Trust), Derralynn Hughes(Royal Free London NHS Foundation Trust), Uma Ramaswami(The Royal Free Hospital), A Mehta(The Royal Free Hospital), Gere Sunder–Plassmann(University of Vienna), Thomas Jansen(Ruhr University Bochum), R. Jaussaud(Hôpital Robert-Debré), Olivier Lidove(Groupe Hospitalier Diaconesses Croix Saint-Simon), Rossella Parini(MRC Epidemiology Unit), Michael Beck(Eastern Illinois University), Guillem Pintos‐Morell(Hospital Universitari Germans Trias i Pujol)
Cited by 178
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|535
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
|Journal of the American Society of Nephrology|2016|421
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364